A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin
OBJECTIVES: I. Determine the effectiveness of low dose docetaxel and carboplatin by response
rate, response duration, and time to progression in patients with stage IIIB or IV non-small
cell lung cancer. II. Determine the side effects and toxicity profile of docetaxel when
given in combination with carboplatin in these patients.
OUTLINE: This is open label study. Patients receive docetaxel IV over 1 hour followed by
carboplatin IV over 30 minutes once a week for 4 weeks. Patients receive at least 2 courses
(8 weeks) of treatment. Courses are further repeated in the absence of unacceptable toxicity
and disease progression.
PROJECTED ACCRUAL: There will be 20-38 patients accrued into this study.
Primary Purpose: Treatment
Raj Sadasivan, MD, PhD
Hope Cancer Institute, Inc.
United States: Federal Government
|Bethany Medical Center||Kansas City, Kansas 66102|
|Heartland Cancer Research Network||Kansas City, Kansas 66102|